Is Automated Insulin Delivery System Therapy Safe and Effectıve in Children Under 7 Years Old?

This study aims to evaluate the off-label use of the MiniMed™ 780G system in children under seven years old. Children under seven years with type 1 diabetes (T1D) using MiniMed™ 780G were retrospectively compared with children of similar age and gender using MiniMed™ 640G and multiple-dose insulin (MDI) therapy with continuous glucose monitoring systems (CGMs). CGM metrics, total daily insulin dose (TDI), and HbA1c levels were evaluated retrospectively at baseline and at the 3rd, 6th, and 12th months. At the initiation of MiniMed™ 780G therapy, the mean age was 5,25±1,22 years (range: 2,8–6,8 years). Glucose management indicator (GMI) and HbA1c remained lower in the MiniMed™ 780G group at the 3rd, 6th, and 12th months compared to baseline (p=0,009 and p